Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 6
2005 1
2006 3
2007 2
2008 2
2009 2
2010 1
2011 3
2012 1
2013 4
2014 7
2015 3
2016 2
2017 5
2018 3
2019 6
2020 8
2021 13
2022 14
2023 12
2024 17
2025 23
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: salutari v. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Olawaiye AB, et al. Among authors: salutari v. Lancet. 2025 Jun 21;405(10496):2205-2216. doi: 10.1016/S0140-6736(25)01040-2. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473448 Clinical Trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26. J Clin Oncol. 2025. PMID: 39591551 Free PMC article. Clinical Trial.
The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barquín A, Gálvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio Pérez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. Alvarez Secord A, et al. Among authors: salutari v. Ann Oncol. 2025 Mar;36(3):321-330. doi: 10.1016/j.annonc.2024.11.011. Epub 2024 Nov 29. Ann Oncol. 2025. PMID: 39617145 Free article. Clinical Trial.
Hyperthermic Intraperitoneal Chemotherapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized Trial on Survival Evaluation (HORSE; MITO-18).
Fagotti A, Costantini B, Fanfani F, Giannarelli D, De Iaco P, Chiantera V, Mandato V, Giorda G, Aletti G, Greggi S, Perrone AM, Salutari V, Trozzi R, Scambia G. Fagotti A, et al. Among authors: salutari v. J Clin Oncol. 2025 Mar;43(7):852-860. doi: 10.1200/JCO.24.00686. Epub 2024 Nov 21. J Clin Oncol. 2025. PMID: 39571127 Clinical Trial.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, Bamias A, Salutari V, Selle F, Frezzini S, De Giorgi U, Pautier P, Bologna A, Orditura M, Dubot C, Gadducci A, Mammoliti S, Ray-Coquard I, Zafarana E, Breda E, Favier L, Ardizzoia A, Cinieri S, Largillier R, Sambataro D, Guardiola E, Lauria R, Pisano C, Raspagliesi F, Scambia G, Daniele G, Perrone F; MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Pignata S, et al. Among authors: salutari v. Lancet Oncol. 2021 Feb;22(2):267-276. doi: 10.1016/S1470-2045(20)30637-9. Lancet Oncol. 2021. PMID: 33539744 Clinical Trial.
Immunotherapy in gynecological cancers.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: salutari v. Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046088 Free PMC article. Review.
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Among authors: salutari v. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Mirza MR, Bjørge L, Marmé F, Christensen RD, Gil-Martin M, Auranen A, Ataseven B, Rubio MJ, Salutari V, Luczak AA, Runnebaum IB, Redondo A, Lindemann K, Trillsch F, Ginesta MPB, Roed H, Kurtz JE, Petersson KS, Nyvang GB, Sehouli J. Mirza MR, et al. Among authors: salutari v. Gynecol Oncol. 2025 Jan;192:128-136. doi: 10.1016/j.ygyno.2024.12.003. Epub 2024 Dec 9. Gynecol Oncol. 2025. PMID: 39657575 Free article. Clinical Trial.
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
Vergote I, Copeland LJ, Van Gorp T, Laenen A, Scambia G, Thaker PH, Cibula D, Colombo N, Lea J, Gonzalez-Martin A, Korach J, Sehouli J, Monk BJ, Heinzelmann-Schwarz V, Berger R, Buscema J, Lau S, Mądry R, Denys H, Pepin JT, Salutari V, Bagaméri A, Ardizzoia A, Henry S, Cecere SC, Hruda M, Iglesias DA, Manso L, Shai A, O'Malley DM; ENGOT-ov50/GOG-3029/INNOVATE-3 Study Investigators. Vergote I, et al. Among authors: salutari v. Eur J Cancer. 2025 Mar 26;219:115306. doi: 10.1016/j.ejca.2025.115306. Epub 2025 Feb 17. Eur J Cancer. 2025. PMID: 40010134 Free article. Clinical Trial.
125 results